Vir Biotechnology, Inc.
VIRNASDAQHealthcare● Active
$8.42
$-0.23(-2.65%)
Market Cap$1.4B
P/E Ratio—
52W High$11.66
52W Low$4.155
Vir Biotechnology, Inc. (VIR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VIR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.85
Est. -$0.01 · -8400.0%
Revenue
$-0.00B
Est. $0.06B · -100.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
VIR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.33 | — | — | — | $0.14B | — |
| ▼ Q2 FY2026 | May 6, 2026 | -$0.01 | -$0.85 | -8400.0% | $-0.00B | $0.06B | -100.0% |
| ▲ Q1 FY2026 | Feb 23, 2026 | -$0.42 | -$0.31 | +26.2% | $0.06B | $0.02B | +221.9% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.70 | -$1.17 | -67.1% | $0.00B | $0.02B | -98.8% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.72 | -$0.80 | -11.1% | $0.00B | $0.00B | -55.4% |
| ▼ Q2 FY2025 | May 7, 2025 | -$0.83 | -$0.88 | -6.0% | $0.00B | $0.01B | -79.1% |
| ▲ Q1 FY2025 | Feb 26, 2025 | -$0.85 | -$0.76 | +10.6% | $0.01B | $0.01B | +52.0% |
| ▼ Q4 FY2024 | Oct 31, 2024 | -$0.96 | -$1.56 | -62.5% | $0.00B | $0.01B | -74.6% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.33
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$0.85
EPS Est.
-$0.01
EPS Surpr.
-8400.0%
Revenue
$-0.00B
Q1 FY2026
Feb 23, 2026Beat
EPS Actual
-$0.31
EPS Est.
-$0.42
EPS Surpr.
+26.2%
Revenue
$0.06B
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$1.17
EPS Est.
-$0.70
EPS Surpr.
-67.1%
Revenue
$0.00B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.80
EPS Est.
-$0.72
EPS Surpr.
-11.1%
Revenue
$0.00B
Q2 FY2025
May 7, 2025Miss
EPS Actual
-$0.88
EPS Est.
-$0.83
EPS Surpr.
-6.0%
Revenue
$0.00B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$0.76
EPS Est.
-$0.85
EPS Surpr.
+10.6%
Revenue
$0.01B
Q4 FY2024
Oct 31, 2024Miss
EPS Actual
-$1.56
EPS Est.
-$0.96
EPS Surpr.
-62.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.66 | $-0.52 | $-0.42 | 3 |
| Q3 FY2028 | $-0.67 | $-0.53 | $-0.43 | 2 |
| Q2 FY2028 | $-0.50 | $-0.40 | $-0.33 | 2 |
| Q1 FY2028 | $-0.49 | $-0.39 | $-0.32 | 3 |
| Q4 FY2027 | $-0.82 | $-0.65 | $-0.53 | 2 |
| Q3 FY2027 | $-0.75 | $-0.60 | $-0.49 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.0B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -8400.0% | $10.01 | $10.29 | +2.80% |
| ▲ Q1 FY2026 | Feb 23, 2026 | +26.2% | $7.56 | $7.43 | -1.72% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -67.1% | $5.25 | $5.40 | +2.86% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -11.1% | $5.11 | $5.08 | -0.59% |
| ▼ Q2 FY2025 | May 7, 2025 | -6.0% | $5.63 | $5.61 | -0.36% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +10.6% | $9.10 | $9.20 | +1.10% |
| ▼ Q4 FY2024 | Oct 31, 2024 | -62.5% | $7.60 | $7.49 | -1.45% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -9.7% | $10.16 | $9.73 | -4.23% |
Q2 FY2026+2.80%
Report Date
May 6, 2026
EPS Beat/Miss
-8400.0%
Price Before
$10.01
Price After
$10.29
Q1 FY2026-1.72%
Report Date
Feb 23, 2026
EPS Beat/Miss
+26.2%
Price Before
$7.56
Price After
$7.43
Q4 FY2025+2.86%
Report Date
Nov 5, 2025
EPS Beat/Miss
-67.1%
Price Before
$5.25
Price After
$5.40
Q3 FY2025-0.59%
Report Date
Aug 6, 2025
EPS Beat/Miss
-11.1%
Price Before
$5.11
Price After
$5.08
Q2 FY2025-0.36%
Report Date
May 7, 2025
EPS Beat/Miss
-6.0%
Price Before
$5.63
Price After
$5.61
Q1 FY2025+1.10%
Report Date
Feb 26, 2025
EPS Beat/Miss
+10.6%
Price Before
$9.10
Price After
$9.20
Q4 FY2024-1.45%
Report Date
Oct 31, 2024
EPS Beat/Miss
-62.5%
Price Before
$7.60
Price After
$7.49
Q3 FY2024-4.23%
Report Date
Aug 1, 2024
EPS Beat/Miss
-9.7%
Price Before
$10.16
Price After
$9.73
Avg Beat Reaction-0.31%
Avg Miss Reaction-0.16%
Beat Rate2 / 8 quarters
Largest Move-4.23% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VIR ends December
Vir Biotechnology, Inc. (VIR) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.85 — missing the analyst consensus of $-0.01 by -8400.0%. The next VIR earnings date is expected around September 1, 2026.
Each quarter, investors track VIR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VIR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VIR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VIR earnings · 5 questionsVir Biotechnology, Inc.'s next earnings report is expected around September 1, 2026. VIR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VIR historically reports after market close (AMC).
VIR earnings datewhen is VIR earningsVIR next earnings datewhen does VIR report earningsVIR earnings calendar
▸ Source: FMP · Vir Biotechnology, Inc. SEC filings · US GAAP · Vir Biotechnology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026